Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives - 2The Best Business visionaries Under 30
- 3Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- 4The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- 5Family Holiday spots
- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
- Former biotech CEO sued over COVID vaccine alleged insider trading
- Doctor's orders? ‘Belly laugh at least two to five days a week'
- A volcanic eruption may have catalyzed the plague's arrival in Europe, study suggests
- Ultra-Orthodox protests erupt across Israel on haredi IDF enlistment day
- Insurance warning signs in doctors’ offices might discourage patients from speaking openly about their health
- Moderna to complete US mRNA manufacturing network with $140 million investment
- I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
- Extraordinary Guinness World Records That Will Astound You
